18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: Effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats

Brain Research

Volumn 719, Issue 1-2, 1996, Pages 29-35

  Glick, S D ^a   Kuehne, M E ^b   Maisonneuve, I M ^a   Bandarage, U K ^b   Molinari, H H ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

18 Methoxycoronaridine; Cocaine; Drug self administration; Iboga alkaloid; Ibogaine; Morphine

Indexed keywords

18 METHOXYCORONARIDINE; ALKALOID; COCAINE; DOPAMINE; IBOGAINE; IBOGAINE DERIVATIVE; MORPHINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CEREBELLUM; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG DEPENDENCE; DRUG SELF ADMINISTRATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTOCHEMISTRY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MESOLIMBIC DOPAMINERGIC SYSTEM; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; TREMOR;

EID: 0029932986     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-8993(96)00056-X     Document Type: Article

References (34)

1. Bornmann, W.G. and Kuehne, M.E., A common intermediate providing syntheses of pseudo-tabersonine, coronaridine, iboxyphylline, ibophyllidine, vinamidine and vinblastine, J. Org. Chem., 57 (1992) 1752.
2. Cappendijk, S.L.T. and Dzoljic, M.R., Inhibitory effects of ibogaine on cocaine self-administration in rats, Eur. J. Pharmacol., 241 (1993) 261-265.
3. Dai, H., Gebhardt, K. and Carey, R.J., Time course effects of MK-801: the relationship between brain neurochemistry and behavior, Brain Res. Bull., 36 (1995) 175-180.
4. Deecher, D.C., Teitler, M., Soderlund, D.M., Bornmann, W.G., Kuehne, M.E. and Glick, S.D., Mechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies, Brain Res., 571 (1992) 242-247.
5. Desclin, J.C., Histological evidence supporting the inferior olive as the major source of cerebellar climbing fibers in the rat, Brain Res., 77 (1974) 365-384.
6. de Montigny, C. and Lamarre, Y., Rhythmic activity induced by harmaline in the olivo-cerebello-bulbar system of the cat, Brain Res., 53 (1973) 81-95.
7. Dhahir, H.I., A Comparative Study of the Toxicity of Ibogaine and Serotonin, Doctoral thesis, Ann Arbor, MI, USA, University Microfilm International (1971) 71-25-341.
8. Dzoljic, E.D., Kaplan, C.D. and Dzoljic, M.R., Effect of ibogaine on naloxone precipitated withdrawal syndrome in chronic morphine dependent rats. Arch. Int. Pharmacodyn. Ther., 294 (1988) 64-70.
9. Fink, R.P. and Heimer, L., Two methods for selective silver impregnation of degenerating axons and their synaptic endings in the central nervous system, Brain Res., 4 (1967) 369-374.
10. Gallagher, C.A., Hough, L.B., Keefner, S.M., Seyed-Mozaffari, A., Archer, S. and Glick, S.D., Identification and quantification of the indole alkaloid ibogaine in biological samples by gas chromatography-mass spectrometry, Biochem. Pharmacol., 49 (1995) 73-79.
11. Glick, S.D. and R.D. Cox, Changes in morphine self-administration after brainstem lesions in rats, Psychopharmacology, 52 (1977), 151-156.
12. Glick, S.D., Dong, N., Keller, Jr., R.W. and Carlson, J.N., Estimating extracellular concentrations of dopamine and 3,4-dihydroxy-phenylacetic acid in nucleus accumbens and striatum using microdialysis: relationships between in vitro and in vivo recoveries, J. Neurochem., 62 (1994) 2017-2021.
13. Glick, S.D., Hinds, P.A. and Carlson, J.N., Food deprivation and stimulant self-administration in rats: differences between cocaine and d-amphetamine. Psychopharmacology, 91 (1987) 372-374.
14. Glick, S.D., Kuehne, M.E., Raucci, J., Wilson, T.E., Larson, T.D., Keller, R.W., and Carlson, J.N., Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum, Brain Res., 657 (1994) 14-22.
15. Glick, S.D. and D.A. Ross, Neuroanatomical substrates of opiate reinforcement: lateralized effects. In: J.E. Smith and J.D. Lane (Eds.), Neurobiology of Opiate Reward Mechanisms, Elsevier, Amsterdam, 1983, pp. 309-330.
16. Glick, S.D., Rossman, K., Rao, N.C., Maisonneuve, I.M. and Carlson, J.N., Effects of ibogaine on acute signs of morphine withdrawal in rats: independence from tremor, Neuropharmacology, 31 (1992) 497-500.
17. Glick, S.D., Rossman, K., Steindorf, S., Maisonneuve, I.M. and Carlson, J.N., Effects and aftereffects of ibogaine on morphine self-administration in rats, Eur. J. Pharmacol., 195 (1991) 341-345.
18. Glick, S.D., Rossman, K., Wang, S., Dong, N. and Keller, R.W., Local effects of ibogaine on extracellular levels of dopamine and its metabolites in nucleus accumbens and striatum: interactions with d-amphetamine, Brain Res., 628 (1993) 201-208.
19. Llinas, R. and Volkind, R.A., The olivo-cerebellar system: functional properties as revealed by harmaline-induced tremor, Exp. Brain Res., 18 (1973) 69-87.
20. Maisonneuve, I.M., Keller, R.W. and Glick, S.D., Interactions between ibogaine, a potential antiaddictive agent, and morphine: an in vivo microdialysis study, Eur. J. Pharmacol., 199 (1991) 35-42.
21. Mash, D.C., Staley, J.K., Baumann, M.H., Rothman, R.B. and Hearn, W.L., Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin, Life Sci., 57 (1995) PL 45-50.
22. Mash, D.C., Staley, J.K., Pablo, J.P., Holohean, A.M., Hackman, J.C. and Davidoff, R.A., Properties of ibogaine and its principal metabolite (12-hyrdoxyibogamine) at the MK-801 binding site of the NMDA receptor complex, Neurosci. Lett., 192 (1995) 53-56.
23. Molinari, H.H., Maisonneuve, I.M. and Glick, S.D., Dose dependence of ibogaine neurotoxicity, Soc. Neurosci. Abstr., 20 (1994) 1236.
24. O'Hearn, E., Long, D.B. and Molliver, M.E., Ibogaine induces glial activation in parasagittal zones of the cerebellum, Neuro Report, 4 (1993) 299-302.
25. O'Hearn, E. and Molliver, M.E., Degeneration of purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline, Neuroscience, 55 (1993) 303-310.
26. Paxinos, G. and Watson, C., The Rat Brain in Stereotaxic Coordinates, Academic Press, Orlando, FL, 1986.
27. Pearl, S.M., Herrick-Davis, K., Teitler, M. and Click, S.D., Radioligand binding study of noribogaine, a likely metabolite of ibogaine, Brain Res., 675 (1995) 342-344.
28. Popik, P., Layer, R.T., Fossom, L.H., Benveniste, M., Geter-Douglass, B., Witkin, J.M. and Skolnick, P., NMDA antagonist properties of the putative antiaddictive drug, ibogaine, J. Pharmacol. Exp. Ther., 275 (1995) 753-760.
29. Popik, P., Layer, R.T. and Skolnick, P., 100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug, Pharmacol. Rev. 47 (1995) 235-253.
30. Sershen, H., Hashim, A. and Lajtha, A., Ibogaine reduces preference for cocaine consumption in C57BL/tBy mice, Pharmacol. Biochem. Behav., 47 (1994) 13-19.
31. Sweetnam, P.M., Lancaster, J., Snowman, A., Collins, J.L., Perschke, S., Bauer, C. and Ferkany, J., Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine's putative anti-addictive activity, Psychopharmacology, 118 (1995) 369-376.
32. Tella, S.R., Effects of monoamine reuptake inhibitors on cocaine self-administration in rats, Pharmacol. Biochem. Behav., 51 (1995) 687-692.
33. Touchette, N., Ibogaine neurotoxicity raises new questions in addiction research, J. NIH Res., 5 (1993) 50-55.
34. Weeks, J.R., Long-term intravenous infusion. In: R.D. Myers (Ed.), Methods in Psychobiology, Vol. 2, Academic Press, New York, 1972, pp. 155-168.